Teclistamab Triplet Shows Manageable Safety, Early Efficacy in Transplant-Ineligible Myeloma

Teclistamab plus daratumumab and lenalidomide had a manageable safety profile in patients with transplant-ineligible, newly diagnosed multiple myeloma.

Related Keywords

France ,United States ,American ,Teclistamab Tecvayli ,Salomon Manier ,American Society For Transplantation ,Lille University Hospital ,International Myeloma Working Group ,Common Terminology Criteria ,Adverse Events ,American Society ,Cellular Therapy ,Safety Run In Cohorts ,